Ichai C, Armando G, Orban JC, Berthier F, Rami L, Samat-Long C, Grimaud D, Leverve XSodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients. Intensive Care Med 35:471-479

Faculté de Médecine and CHU de Nice, Service de Réanimation, Hôpital Saint-Roch, Nice Cedex 1, France.
Intensive Care Medicine (Impact Factor: 7.21). 09/2008; 35(3):471-9. DOI: 10.1007/s00134-008-1283-5
Source: PubMed


Traumatic brain injury (TBI) is still a major cause of mortality and morbidity. Recent trials have failed to demonstrate a beneficial outcome from therapeutic treatments such as corticosteroids, hypothermia and hypertonic saline. We investigated the effect of a new hyperosmolar solution based on sodium lactate in controlling raised intracranial pressure (ICP).
Prospective open randomized study in an adult ICU.
Thirty-four patients with isolated severe TBI (Glasgow Coma Scale <or= 8) and intracranial hypertension were allocated to receive equally hyperosmolar and isovolumic therapy, consisting of either mannitol or sodium lactate. Rescue therapy by crossover to the alternative treatment was indicated when ICP could not be controlled. The primary endpoint was efficacy in lowering ICP after 4 h, with a secondary endpoint of the percentage of successfully treated episodes of intracranial hypertension. The analysis was performed with both intention-to-treat and actual treatments provided.
Compared to mannitol, the effect of the lactate solution on ICP was significantly more pronounced (7 vs. 4 mmHg, P = 0.016), more prolonged (fourth-hour-ICP decrease: -5.9 +/- 1 vs. -3.2 +/- 0.9 mmHg, P = 0.009) and more frequently successful (90.4 vs. 70.4%, P = 0.053).
Acute infusion of a sodium lactate-based hyperosmolar solution is effective in treating intracranial hypertension following traumatic brain injury. This effect is significantly more pronounced than that of an equivalent osmotic load of mannitol. Additionally, in this specific group of patients, long-term outcome was better in terms of GOS in those receiving as compared to mannitol. Larger trials are warranted to confirm our findings.

Download full-text


Available from: Jean-Christophe Orban, Nov 26, 2014
  • Source
    • "Both studies concluded that infused lactate was effectively metabolized after TBI (Bouzat et al. 2014; Carpenter et al. 2014). Exogenous lactate was found to dilate cerebral vasculature and increase cerebral blood flow (Gordon et al. 2008) and lactate infusion compared favorably to mannitol in reducing ICP after TBI (Ichai et al. 2009). However, the acceptance of this lactate augmentation intervention strategy is still being debated (Nordstrom and Nielsen 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Traumatic brain injury (TBI) is still the leading cause of disability in young adults worldwide. The major mechanisms - diffuse axonal injury, cerebral contusion, ischemic neurological damage, and intracranial hematomas have all been shown to be associated with mitochondrial dysfunction in some form. Mitochondrial dysfunction in TBI patients is an active area of research, and attempts to manipulate neuronal/astrocytic metabolism to improve outcomes have been met with limited translational success. Previously, several preclinical and clinical studies on TBI induced mitochondrial dysfunction have focused on opening of the mitochondrial permeability transition pore (PTP), consequent neurodegeneration and attempts to mitigate this degeneration with cyclosporine A (CsA) or analogous drugs, and have been unsuccessful. Recent insights into normal mitochondrial dynamics and into diseases such as inherited mitochondrial neuropathies, sepsis and organ failure could provide novel opportunities to develop mitochondria-based neuroprotective treatments that could improve severe TBI outcomes. This review summarizes those aspects of mitochondrial dysfunction underlying TBI pathology with special attention to models of penetrating traumatic brain injury, an epidemic in modern American society.
    Journal of Bioenergetics 10/2014; 47(1-2). DOI:10.1007/s10863-014-9589-1 · 3.21 Impact Factor
    • "Although equimolar infusion of 20% mannitol is as effective as 7.45% hypertonic saline (HSS) in decreasing ICP in patients with brain injury but in patients with severe TBI and elevated ICP refractory to previous mannitol treatment, 7.5% hypertonic saline administration showed a significant increase in brain oxygenation and improved cerebral and systemic hemodynamics.[2428] Small trials have also investigated the effects of other hyperosmolar solutions including sodium bicarbonate and sodium lactate and these agents were found to have similar effects as mannitol or hypertonic saline.[29] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Traumatic brain injury (TBI) is a major global problem and affects approximately 10 million peoples annually; therefore has a substantial impact on the health-care system throughout the world. In this article, we have summarized various aspects of specific intensive care management in patients with TBI including the emerging evidence mainly after the Brain Trauma Foundation (BTF) 2007 and also highlighted the scope of the future therapies. This review has involved the relevant clinical trials and reviews (from 1 January 2007 to 31 March 2013), which specifically discussed about the topic. Though, BTF guideline based management strategies could provide standardized protocols for the management of patients with TBI and have some promising effects on mortality and morbidity; there is still need of inclusion of many suggestions based on various published after 2007. The main focus of majority of these trials remained to prevent or to treat the secondary brain injury. The future therapy will be directed to treat injured neurons and may benefit the outcome. There is also urgent need to develop some good prognostic indicators as well.
    03/2014; 8(2):268-275. DOI:10.4103/1658-354X.130746
  • Source
    • "Editorial [19] "

    Journal of Hepatology 12/2013; 60(3). DOI:10.1016/j.jhep.2013.11.029 · 11.34 Impact Factor
Show more